Upper Gastrointestinal Bleed Management

Initial Assessment and Resuscitation

The American College of Gastroenterology recommends hemodynamic stabilization as the first priority before any diagnostic workup, with establishment of two large-bore IV cannulae in the anticubital fossae immediately for all patients with hematemesis 1, 2
The American College of Gastroenterology suggests assessing severity using vital signs, with pulse >100 bpm, systolic BP <100 mmHg, or hemoglobin <100 g/L indicating severe bleeding requiring intensive monitoring 1, 2
The European Society of Gastrointestinal Endoscopy recommends calculating the shock index (heart rate/systolic BP), with a value >1 indicating hemodynamic instability and high-risk status 3

The American College of Gastroenterology states that young patients (<60 years) with normal vital signs and hemoglobin >100 g/L represent mild-to-moderate bleeding and can be managed on a general medical ward with hourly vital sign monitoring 1, 2
The American College of Gastroenterology recommends using the Rockall score, with a score <3 associated with excellent prognosis and a score >8 indicating high mortality risk 1, 2

The American College of Gastroenterology suggests infusing normal saline to achieve falling pulse rate, rising blood pressure, and adequate urine output (>30 mL/hour) 1, 2
The American College of Gastroenterology recommends transfusing red blood cells when hemoglobin <70-80 g/L using restrictive thresholds 4, 5

The American College of Gastroenterology recommends administering intravenous proton pump inhibitor (PPI) therapy before endoscopy to potentially downstage the lesion 4, 5

The American Society for Gastrointestinal Endoscopy recommends that upper endoscopy must be performed within 24 hours of presentation for all patients with UGI bleeding 4, 6, 5
The American College of Radiology suggests that stable patients (normal vitals, hemoglobin >100 g/L) can safely undergo endoscopy on the next elective morning list 7, 1

The American College of Gastroenterology recommends that patients requiring endoscopic therapy for high-risk lesions should receive high-dose IV PPI with bolus followed by continuous infusion 4, 5
The American College of Gastroenterology suggests that high-risk patients should be hospitalized for at least 72 hours after endoscopic hemostasis 4, 5

The American College of Gastroenterology recommends that recurrent bleeding after initial endoscopic therapy warrants repeat endoscopy as the first-line approach 4
The American College of Gastroenterology suggests that persistent or recurrent bleeding after second endoscopy requires interventional radiology (angiography with embolization) or surgery 4

In the early hours of acute upper gastrointestinal bleeding, hemoglobin concentrations may remain unchanged despite substantial blood loss because plasma equilibration is delayed; therefore clinical assessment of perfusion and shock should guide management rather than the initial hemoglobin value alone. Evidence level: moderate quality (multiple cohort analyses) 8.
Transfusion decisions should not be based solely on the current hemoglobin measurement; clinicians must also consider the predicted decline in hemoglobin and the patient’s hemodynamic and clinical status. Evidence level: moderate quality (prospective observational data) 9.

For hemodynamically stable patients without cardiovascular disease, a restrictive transfusion strategy is recommended, transfusing when hemoglobin falls below 70 g/L and aiming for a target range of 70–90 g/L. Evidence level: high‑quality randomized trial (restrictive vs liberal strategy) 10.
In patients with known or suspected cardiovascular disease, a more liberal threshold of 80 g/L is advised, with a target hemoglobin of 80–100 g/L, to reduce the risk of ischemic cardiac events. Evidence level: low‑quality evidence (under‑powered subgroup analyses) 8.
Initial hemoglobin values obtained within the first few hours after acute bleeding should not be used in isolation to gauge blood loss, because hemodilution may mask true volume loss; ongoing clinical signs of shock must be interpreted alongside laboratory data. Evidence level: moderate quality (prospective cohort) 11.

Cirrhotic patients (Child‑Pugh class A or B) benefit from a restrictive transfusion approach, which is associated with a markedly lower hazard of death (hazard ratio ≈ 0.30). These patients also require more frequent hemoglobin monitoring due to an elevated risk of re‑bleeding. Evidence level: moderate quality (multicenter cohort) 12.
For patients with cardiovascular disease, a higher transfusion threshold (80–100 g/L) may be prudent, although the supporting data are of low quality and derived from subgroup analyses. Evidence level: low‑quality evidence (post‑hoc analyses) 9.